Decoupling Discrimination from Calibration: A Platform-Resilient, Uncertainty-Aware Transcriptomic Biomarker for Estrogen Receptor Phenotyping in Breast Cancer

Background: Estrogen receptor alpha (ERα, encoded by ESR1) guides endocrine therapy eligibility for roughly 70–80% of breast cancer patients worldwide. Although immunohistochemistry (IHC) remains the clinical reference standard, pre-analytical tissue handling, cold ischemia delays, differences in antibody affinity, and subjective visual scoring contribute to a 5–10% diagnostic discordance rate. High-throughput transcriptomics provides an objective diagnostic alternative, yet existing machine-learning classifiers frequently suffer from cross-platform performance decay, unstable feature selection in high dimensions, and a critical vulnerability we define as the discrimination-calibration paradox—where models maintain high rank discrimination (>0.95 AUROC) while outputting severely distorted, uncalibrated risk probabilities under domain shift. Methods: We developed and evaluated the RAPID-ER framework across 4,218 rigorously audited breast cancer profiles from three independent cohorts: TCGA-BRCA (N = 1,044, primary discovery and 5-fold cross-validation), SCAN-B / GSE96058 (N = 3,073, external RNA-seq validation), and GSE42568 (N = 101, cross-platform Affymetrix microarray stress-test). Across a shared 17,367-gene feature space, we constructed the Stability-Selected Multilayer Perceptron (SS-MLP), combining 100-iteration repeated Elastic-Net bootstrap subsampling with a regularized deep neural network (256–64 GELU architecture). Two domain transfer strategies were benchmarked: parametric frozen training standardization (Strategy A) and label-free within-sample relative rank normalization (Strategy B). Probability calibration was assessed via Sanders/Murphy Brier score decomposition, Expected Calibration Error (ECE), and selective classification abstention. Results: Under internal 5-fold cross-validation on TCGA-BRCA, SS-MLP achieved an out-of-fold AUROC of 0.9560 [95% CI: 0.938, 0.970], AUPRC of 0.9851 [0.977, 0.991], Sensitivity of 92.07%, Specificity of 93.67%, and Brier score of 0.0675. In independent external RNA-seq validation (GSE96058, N = 3,073), univariate ESR1 models failed under frozen standardization: despite an AUROC of 0.9604, probability calibration degraded severely (ECE = 0.4290, Intercept = 5.2361), causing sensitivity to drop to 58.44% and misclassifying 1,177 true ER-positive patients. Conversely, SS-MLP preserved both high discrimination (AUROC 0.9500 [0.933, 0.965], Sensitivity 97.74%) and tight calibration, reducing calibration error by more than 10-fold (ECE = 0.0396, Brier = 0.0396). On cross-platform microarrays (GSE42568, N = 101), frozen standardization failed completely due to probe dynamic range compression (ESR1 Sensitivity 0.0000, Brier 0.6188). Within-sample rank normalization (Strategy B) restored cross-platform utility without retraining, lifting SS-MLP AUROC to 0.7943 [0.701, 0.874] and AUPRC to 0.8773. An in silico ESR1-exclusion ablation demonstrated complete downstream transcriptomic redundancy (AUROC 0.9608, AUPRC 0.9863). Finally, automated confidence triage with selective abstention achieved 99.6% autonomous coverage with a 3.92% error rate (falling to 2.06% at τ = 0.95), safely routing equivocal borderline cases for confirmatory pathology review. Conclusions: Strong rank discrimination can mask severe probability miscalibration under genomic domain shift. By integrating stability-selected multi-gene networks with label-free rank normalization and uncertainty-based abstention, RAPID-ER resolves the discrimination-calibration paradox and establishes an open, platform-resilient decision-support benchmark for precision oncology.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24365062
Primary Topic
Breast Cancer Treatment Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Decoupling Discrimination from Calibration: A Platform-Resilient, Uncertainty-Aware Transcriptomic Biomarker for Estrogen Receptor Phenotyping in Breast Cancer

Gautam Kunniyur Ramchander
Zenodo (CERN European Organization for Nuclear Research)
Breast Cancer Treatment Studies
preprint

Decoupling Discrimination from Calibration: A Platform-Resilient, Uncertainty-Aware Transcriptomic Biomarker for Estrogen Receptor Phenotyping in Breast Cancer

Gautam Kunniyur Ramchander
preprint en

Abstract

Background: Estrogen receptor alpha (ERα, encoded by ESR1) guides endocrine therapy eligibility for roughly 70–80% of breast cancer patients worldwide. Although immunohistochemistry (IHC) remains the clinical reference standard, pre-analytical tissue handling, cold ischemia delays, differences in antibody affinity, and subjective visual scoring contribute to a 5–10% diagnostic discordance rate. High-throughput transcriptomics provides an objective diagnostic alternative, yet existing machine-learning classifiers frequently suffer from cross-platform performance decay, unstable feature selection in high dimensions, and a critical vulnerability we define as the discrimination-calibration paradox—where models maintain high rank discrimination (>0.95 AUROC) while outputting severely distorted, uncalibrated risk probabilities under domain shift. Methods: We developed and evaluated the RAPID-ER framework across 4,218 rigorously audited breast cancer profiles from three independent cohorts: TCGA-BRCA (N = 1,044, primary discovery and 5-fold cross-validation), SCAN-B / GSE96058 (N = 3,073, external RNA-seq validation), and GSE42568 (N = 101, cross-platform Affymetrix microarray stress-test). Across a shared 17,367-gene feature space, we constructed the Stability-Selected Multilayer Perceptron (SS-MLP), combining 100-iteration repeated Elastic-Net bootstrap subsampling with a regularized deep neural network (256–64 GELU architecture). Two domain transfer strategies were benchmarked: parametric frozen training standardization (Strategy A) and label-free within-sample relative rank normalization (Strategy B). Probability calibration was assessed via Sanders/Murphy Brier score decomposition, Expected Calibration Error (ECE), and selective classification abstention. Results: Under internal 5-fold cross-validation on TCGA-BRCA, SS-MLP achieved an out-of-fold AUROC of 0.9560 [95% CI: 0.938, 0.970], AUPRC of 0.9851 [0.977, 0.991], Sensitivity of 92.07%, Specificity of 93.67%, and Brier score of 0.0675. In independent external RNA-seq validation (GSE96058, N = 3,073), univariate ESR1 models failed under frozen standardization: despite an AUROC of 0.9604, probability calibration degraded severely (ECE = 0.4290, Intercept = 5.2361), causing sensitivity to drop to 58.44% and misclassifying 1,177 true ER-positive patients. Conversely, SS-MLP preserved both high discrimination (AUROC 0.9500 [0.933, 0.965], Sensitivity 97.74%) and tight calibration, reducing calibration error by more than 10-fold (ECE = 0.0396, Brier = 0.0396). On cross-platform microarrays (GSE42568, N = 101), frozen standardization failed completely due to probe dynamic range compression (ESR1 Sensitivity 0.0000, Brier 0.6188). Within-sample rank normalization (Strategy B) restored cross-platform utility without retraining, lifting SS-MLP AUROC to 0.7943 [0.701, 0.874] and AUPRC to 0.8773. An in silico ESR1-exclusion ablation demonstrated complete downstream transcriptomic redundancy (AUROC 0.9608, AUPRC 0.9863). Finally, automated confidence triage with selective abstention achieved 99.6% autonomous coverage with a 3.92% error rate (falling to 2.06% at τ = 0.95), safely routing equivocal borderline cases for confirmatory pathology review. Conclusions: Strong rank discrimination can mask severe probability miscalibration under genomic domain shift. By integrating stability-selected multi-gene networks with label-free rank normalization and uncertainty-based abstention, RAPID-ER resolves the discrimination-calibration paradox and establishes an open, platform-resilient decision-support benchmark for precision oncology.

Zenodo (CERN European Organization for Nuclear Research)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon